Cardiac tissue engineering for the treatment of heart failure post-infarction

Jacqueline S. Wendel, Robert T. Tranquillo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cell-based therapy has become an attractive solution to the high incidence of heart failure post-infarction. Many current approaches to cell delivery post-infarction result in poor cell engraftment resulting in limited functional benefits. Thus, the use of engineered tissues to deliver cells to the injured myocardium or replace myocardium post infarction has been a topic of increasing interest. Tissue engineering provides a platform for the delivery of a large number of cells to the injured myocardium with high retention, allowing for in vitro development of cellular organization, intracellular communication and ECM deposition. This chapter will discuss the currently used methods to create engineered cardiac tissues, including scaffolds, cells, and cellular conditioning. This chapter will also review the efficacy of these patches in limiting left ventricular remodeling post-infarction in vivo.

Original languageEnglish (US)
Title of host publicationCardiac Fibrosis and Heart Failure
Subtitle of host publicationCause or Effect?
PublisherSpringer International Publishing
Pages405-418
Number of pages14
ISBN (Electronic)9783319174372
ISBN (Print)9783319174365
DOIs
StatePublished - Jan 1 2015

Fingerprint

Military electronic countermeasures
Tissue Engineering
Treatment Failure
Tissue engineering
Infarction
Heart Failure
Tissue
Myocardium
Communication
Tissue Scaffolds
Ventricular Remodeling
Cell- and Tissue-Based Therapy
Cell Count
Incidence

Keywords

  • Biomaterials
  • Bioreactor conditioning
  • Cyclic stretch
  • Electrical stimulation
  • Embryonic stem cells
  • Endothelial cells
  • Induced pluripotent stem cells
  • Myocardial infarction
  • Perfusion
  • Tissue engineering

Cite this

Wendel, J. S., & Tranquillo, R. T. (2015). Cardiac tissue engineering for the treatment of heart failure post-infarction. In Cardiac Fibrosis and Heart Failure: Cause or Effect? (pp. 405-418). Springer International Publishing. https://doi.org/10.1007/978-3-319-17437-2_20

Cardiac tissue engineering for the treatment of heart failure post-infarction. / Wendel, Jacqueline S.; Tranquillo, Robert T.

Cardiac Fibrosis and Heart Failure: Cause or Effect?. Springer International Publishing, 2015. p. 405-418.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wendel, JS & Tranquillo, RT 2015, Cardiac tissue engineering for the treatment of heart failure post-infarction. in Cardiac Fibrosis and Heart Failure: Cause or Effect?. Springer International Publishing, pp. 405-418. https://doi.org/10.1007/978-3-319-17437-2_20
Wendel JS, Tranquillo RT. Cardiac tissue engineering for the treatment of heart failure post-infarction. In Cardiac Fibrosis and Heart Failure: Cause or Effect?. Springer International Publishing. 2015. p. 405-418 https://doi.org/10.1007/978-3-319-17437-2_20
Wendel, Jacqueline S. ; Tranquillo, Robert T. / Cardiac tissue engineering for the treatment of heart failure post-infarction. Cardiac Fibrosis and Heart Failure: Cause or Effect?. Springer International Publishing, 2015. pp. 405-418
@inbook{3cb3db19ca3b424881fca7830bdea96c,
title = "Cardiac tissue engineering for the treatment of heart failure post-infarction",
abstract = "Cell-based therapy has become an attractive solution to the high incidence of heart failure post-infarction. Many current approaches to cell delivery post-infarction result in poor cell engraftment resulting in limited functional benefits. Thus, the use of engineered tissues to deliver cells to the injured myocardium or replace myocardium post infarction has been a topic of increasing interest. Tissue engineering provides a platform for the delivery of a large number of cells to the injured myocardium with high retention, allowing for in vitro development of cellular organization, intracellular communication and ECM deposition. This chapter will discuss the currently used methods to create engineered cardiac tissues, including scaffolds, cells, and cellular conditioning. This chapter will also review the efficacy of these patches in limiting left ventricular remodeling post-infarction in vivo.",
keywords = "Biomaterials, Bioreactor conditioning, Cyclic stretch, Electrical stimulation, Embryonic stem cells, Endothelial cells, Induced pluripotent stem cells, Myocardial infarction, Perfusion, Tissue engineering",
author = "Wendel, {Jacqueline S.} and Tranquillo, {Robert T.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-17437-2_20",
language = "English (US)",
isbn = "9783319174365",
pages = "405--418",
booktitle = "Cardiac Fibrosis and Heart Failure",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Cardiac tissue engineering for the treatment of heart failure post-infarction

AU - Wendel, Jacqueline S.

AU - Tranquillo, Robert T.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Cell-based therapy has become an attractive solution to the high incidence of heart failure post-infarction. Many current approaches to cell delivery post-infarction result in poor cell engraftment resulting in limited functional benefits. Thus, the use of engineered tissues to deliver cells to the injured myocardium or replace myocardium post infarction has been a topic of increasing interest. Tissue engineering provides a platform for the delivery of a large number of cells to the injured myocardium with high retention, allowing for in vitro development of cellular organization, intracellular communication and ECM deposition. This chapter will discuss the currently used methods to create engineered cardiac tissues, including scaffolds, cells, and cellular conditioning. This chapter will also review the efficacy of these patches in limiting left ventricular remodeling post-infarction in vivo.

AB - Cell-based therapy has become an attractive solution to the high incidence of heart failure post-infarction. Many current approaches to cell delivery post-infarction result in poor cell engraftment resulting in limited functional benefits. Thus, the use of engineered tissues to deliver cells to the injured myocardium or replace myocardium post infarction has been a topic of increasing interest. Tissue engineering provides a platform for the delivery of a large number of cells to the injured myocardium with high retention, allowing for in vitro development of cellular organization, intracellular communication and ECM deposition. This chapter will discuss the currently used methods to create engineered cardiac tissues, including scaffolds, cells, and cellular conditioning. This chapter will also review the efficacy of these patches in limiting left ventricular remodeling post-infarction in vivo.

KW - Biomaterials

KW - Bioreactor conditioning

KW - Cyclic stretch

KW - Electrical stimulation

KW - Embryonic stem cells

KW - Endothelial cells

KW - Induced pluripotent stem cells

KW - Myocardial infarction

KW - Perfusion

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=84943386247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943386247&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-17437-2_20

DO - 10.1007/978-3-319-17437-2_20

M3 - Chapter

SN - 9783319174365

SP - 405

EP - 418

BT - Cardiac Fibrosis and Heart Failure

PB - Springer International Publishing

ER -